alexa
Reach Us +1 218 451 2974
A Recombinant Human IgM Prevents Neuronal Injury In Multiple Animal Models Of CNS Disease | 11767
ISSN: 2155-9562

Journal of Neurology & Neurophysiology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

22nd Annual Congress on Neonatology & Pediatrics

Osaka, Japan

International Congress on Neurology

Auckland, New Zealand
Share This Page

A recombinant human IgM prevents neuronal injury in multiple animal models of CNS disease

2nd International Conference and Exhibition on Neurology & Therapeutics

Moses Rodriguez

Keynote: J Neurol Neurophysiol

DOI: 10.4172/2155-9562.S1.009

Abstract
We discovered rHIgM12, a recombinant form of a neuron-binding human antibody that induced neurite extension and neuronal protection in vitro and proved effective in delaying deterioration in multiple animal models of CNS injury. Identified in a patient with Walden strom?s macro globulinemia, the antibody was sequenced and re-expressed in CHO cells to generate a fully human GMP-quality monoclonal antibody. We tested rHIgM12 in three experimental models of CNS injury: 1) chronic, demyelinating/axonal model of multiple sclerosis induced by Theiler?s virus infection; 2) genetic model of ALS caused by transgenic expression of superoxide dismutase (SOD) human mutation; and 3) a model of thromboembolic stroke. In the chronic demyelinating axonal injury model, a single peripheral treatment of antibody improved spontaneous neurological function and prevented axonal loss at the mid-thoracic spinal cord. In the ALS model, antibody treatment prolonged survival and prevented loss of NeuN-stained anterior horn cells. In the thromboembolic stroke model, antibody treatment given 30 minutes post ischemic insult, improved neurologic function closely mimicking clinical application. Studies of mixed brain glial cells in vitro in normoxic and hypoxic conditions showed rHIgM12 in the media activated microglial cells and prevented cell apoptosis by down-regulating caspase expression. Using surface plasmon resonance (SPR), we quantitated binding kinetics of therapeutic antibodies to antigens within the cell membrane. In summary, these results present the first clear demonstration of a recombinant human monoclonal antibody that can ameliorate neuronal injury across experimental models of neuron-destructive human diseases during the evolution of the disease process.
Biography
Moses Rodriguez is a Professor of Neurology and Immunology. He received his M.D. from NorthwesternUniversity. After Neurology residency at Mayo, he completed an NIH fellowship at UCSD and the Scripps Research Institute. His scientific interests include CNS remyelination and experimental neuropathology. Currently principal investigator of five grants and author of >370 peer- reviewed papers, he directs a prestigious National MS Society Center of Excellence and the Mayo Center for Multiple Sclerosis and Central Nervous System Demyelinating Diseases Research and Therapeutics. He is a Mayo Clinic distinguished investigator and received the Frontiers in Neuroscience award from the American Academy of Neurology.
Relevant Topics
Top